187 PRE-OPERATIVE URINARY PROSTATE CANCER GENE 3 (PCA3) IS PREDICTING PATHOLOGICALLY CONFIRMED SMALL VOLUME AND INSIGNIFICANT PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Staging1 Apr 2011187 PRE-OPERATIVE URINARY PROSTATE CANCER GENE 3 (PCA3) IS PREDICTING PATHOLOGICALLY CONFIRMED SMALL VOLUME AND INSIGNIFICANT PROSTATE CANCER Marco Auprich, John F. Ward, Richard Babaian, Karl Pummer, Herbert Augustin, Ferdinand Luger, Stefan Gutschi, Hartwig Huland, and Alexander Haese Marco AuprichMarco Auprich Graz, Austria More articles by this author , John F. WardJohn F. Ward Houston, TX More articles by this author , Richard BabaianRichard Babaian Houston, TX More articles by this author , Karl PummerKarl Pummer Graz, Austria More articles by this author , Herbert AugustinHerbert Augustin Graz, Austria More articles by this author , Ferdinand LugerFerdinand Luger Graz, Austria More articles by this author , Stefan GutschiStefan Gutschi Graz, Austria More articles by this author , Hartwig HulandHartwig Huland Hamburg, Germany More articles by this author , and Alexander HaeseAlexander Haese Hamburg, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.257AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prostate CAncer Gene 3 (PCA3) score was recently identified to predict small volume [tumor volume (TV) < 0.5ml] and pathologically insignificant prostate cancer (IPCa) prior to RP. Objective was to evaluate PCA3's potential to improve the multivariable accuracy in the prediction of pathological TV< 0.5ml and IPCa in a US-European cohort. METHODS Complete retrospective clinical and pathological data of consecutive RP men form two two referral centres including pre-operative PCA3 scores and computerized-assisted planimetrically measured tumor volume data were available in 160 patients. PCA3 scores were assessed using the Progensa assay®. Beyond standard risk factors (age, DRE, PSA, prostate volume, biopsy Gleason score, percent positive cores), five different PCA3 codings (continuously and cut-off 17, 24, 35, 47) were used in logistic regression models to identify five distinct pathological endpoints: a) low volume disease (<0.5ml), b) insignificant PCa according to the Epstein criteria. Accuracy estimates of each endpoint were quantified using the area under the curve (AUC) of the receiver operator characteristic (ROC) analysis in models with and without PCA3. RESULTS Tumor volume <0.5 ml and pathological IPCa was present in 21.2% (n=34) and 10% (n=16) of patients .PCA3 scores were significantly lower in low volume disease and insignificant PCa (p≤0.001). AUC of multivariable low volume disease (+2.4 to +5.5%) and insignificant PCa-models (+3 to +3.9%) increased when PCA3 was added to standard clinical risk factors. CONCLUSIONS PCA3 was confirmed as valuable predictor of pathologically confirmed low volume disease and insignificant PCa. Further exploration of its role as an additive marker to select patients for active surveillance may be warranted. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e77 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Marco Auprich Graz, Austria More articles by this author John F. Ward Houston, TX More articles by this author Richard Babaian Houston, TX More articles by this author Karl Pummer Graz, Austria More articles by this author Herbert Augustin Graz, Austria More articles by this author Ferdinand Luger Graz, Austria More articles by this author Stefan Gutschi Graz, Austria More articles by this author Hartwig Huland Hamburg, Germany More articles by this author Alexander Haese Hamburg, Germany More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...